Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Oct. 20 — The FDA plans to update its regulatory language (21 C.F.R. Part 50) in concert with the governmentwide effort to modernize rules governing the use of human subjects in research, the agency's good clinical practice director said Oct. 20.
Joanne Less said the Food and Drug Administration's revisions will be harmonized with the Department of Health and Human Services' proposed changes to its human subject protection regulations known as the Common Rule (45 C.F.R. Part 46). The FDA wasn't one of the 16 agencies listed on the notice of proposed rulemaking that went out Sept. 2.
During an HHS public town hall meeting on the proposed rule, Less said the FDA has received a number of inquiries about the status of its regulations. She confirmed that the agency is working on a parallel effort with the NPRM and asked that any comments on the HHS proposal also take the FDA's regulations into account.
Less is the director of the FDA Office of Good Clinical Practice. She is also the FDA's ex-officio member of the HHS Secretary's Advisory Committee on Human Subject Protections.
The NPRM, “Federal Policy for the Protection of Human Subjects,” is designed to update regulations that have been in place since 1991 to account for the evolution of the research enterprise and new disciplines and new technologies, such as whole genome sequencing. The HHS, along with the 15 other federal departments and agencies, whose authority to oversee clinical trials would broaden under the proposed rule, said in the summary that the changes are designed to build public trust in the research system.
There are currently 18 federal entities signed on to the Common Rule, but Jerry Menikoff, director of the HHS Office for Human Research Protections, said during the town hall meeting that the list is set to expand as the Department of Labor has agreed to adopt the rule as well. The DOL was among the departments and agencies listed in the NPRM.
To contact the reporter on this story: Jeannie Baumann in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Randy Kubetin at email@example.com
More information on the proposed rule, including the town hall meeting, is available at http://www.hhs.gov/ohrp/humansubjects/regulations/nprmhome.html.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)